Search

Your search keyword '"Jett, James R."' showing total 23 results
Start Over Author "Jett, James R." Publisher wiley
23 results on '"Jett, James R."'

4. Road ahead to respiratory health: Experts chart future research directions

Author

HEFFNER, John E., primary, HOLGATE, Stephen T., additional, CHUNG, Kian Fan, additional, NIEDERMAN, Michael S., additional, DALEY, Charles L., additional, JETT, James R., additional, STRADLING, John R., additional, WELLS, Athol U., additional, LIGHT, Richard W., additional, TAPSON, Victor F., additional, HANSELL, David M., additional, PROVONOST, Peter J., additional, and LEE, Y.C. Gary, additional

Published
2009
Full Text
View/download PDF

5. Prognostic factors differ by tumor stage for small cell lung cancer

Author

Foster, Nathan R., primary, Mandrekar, Sumithra J., additional, Schild, Steven E., additional, Nelson, Garth D., additional, Rowland, Kendrith M., additional, Deming, Richard L., additional, Kozelsky, Timothy F., additional, Marks, Randolph S., additional, Jett, James R., additional, and Adjei, Alex A., additional

Published
2009
Full Text
View/download PDF

9. A prognostic model for advanced stage nonsmall cell lung cancer

Author

Mandrekar, Sumithra J., primary, Schild, Steven E., additional, Hillman, Shauna L., additional, Allen, Katie L., additional, Marks, Randolph S., additional, Mailliard, James A., additional, Krook, James E., additional, Maksymiuk, Andrew W., additional, Chansky, Kari, additional, Kelly, Karen, additional, Adjei, Alex A., additional, and Jett, James R., additional

Published
2006
Full Text
View/download PDF

10. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly

Author

Schild, Steven E., primary, Stella, Philip J., additional, Brooks, Burke J., additional, Mandrekar, Sumithra, additional, Bonner, James A., additional, McGinnis, William L., additional, Mailliard, James A., additional, Krook, James E., additional, Deming, Richard L., additional, Adjei, Alex A., additional, Jatoi, Aminah, additional, and Jett, James R., additional

Published
2005
Full Text
View/download PDF

16. Phase II trial of edatrexate in small cell lung cancer

Author

Wiesenfeld, Martin, primary, Jett, James R., additional, Su, John Q., additional, Braich, Theodore A., additional, Kardinal, Carl G., additional, Mailliard, James A., additional, Veeder, Michael H., additional, Morton, Roscoe F., additional, and Michalak, John C., additional

Published
1994
Full Text
View/download PDF

17. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the north central cancer treatment group

Author

Gesme, Dean H., primary, Jett, James R., additional, Schreffler, Dennis D., additional, Su, John Q., additional, Mailliard, James A., additional, Foley, John F., additional, Krook, James E., additional, Maksymiuk, Andrew W., additional, Hatfield, Alan K., additional, Ebbert, Larry P., additional, Pfeifle, Delano M., additional, Morton, Roscoe F., additional, Tschetter, Loren K., additional, and Schaefer, Paul I., additional

Published
1993
Full Text
View/download PDF

18. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma

Author

Veeder, Michael H., primary, Jett, James R., additional, Su, John Q., additional, Mailliard, James A., additional, Foley, John F., additional, Dalton, Robert J., additional, Etzell, Paul S., additional, Marschke, Robert F., additional, Kardinal, Carl G., additional, Maksymiuk, Andrew W., additional, Ebbert, Larry P., additional, Tazelaar, Henry D., additional, and Witrak, Geof A., additional

Published
1992
Full Text
View/download PDF

22. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Author

Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, and Mandrekar SJ

Subjects
Adult, Aged, Aged, 80 and over, Biomarkers analysis, Biomarkers, Tumor analysis, Clinical Trials, Phase II as Topic statistics & numerical data, Clinical Trials, Phase III as Topic statistics & numerical data, Disease-Free Survival, Female, Humans, Lung Neoplasms diagnosis, Male, Middle Aged, Prognosis, Randomized Controlled Trials as Topic statistics & numerical data, Small Cell Lung Carcinoma diagnosis, Survival Analysis, Treatment Outcome, United States epidemiology, Lung Neoplasms mortality, Lung Neoplasms therapy, Small Cell Lung Carcinoma mortality, Small Cell Lung Carcinoma therapy
Abstract

Background: The authors investigated the putative surrogate endpoints of best response, complete response (CR), confirmed response, and progression-free survival (PFS) for associations with overall survival (OS), and as possible surrogate endpoints for OS., Methods: Individual patient data from 870 untreated extensive stage small-cell lung cancer patients participating in 6 single-arm (274 patients) and 3 randomized trials (596 patients) were pooled. Patient-level associations between putative surrogate endpoints and OS were assessed by Cox models using landmark analyses. Trial-level surrogacy of putative surrogate endpoints were assessed by the association of treatment effects on OS and individual putative surrogate endpoints. Trial-level surrogacy measures included: R(2) from weighted least squares regression model, Spearman correlation coefficient, and R(2) from bivariate survival model (Copula R(2) )., Results: Median OS and PFS were 9.6 (95% confidence interval [CI], 9.1-10.0) and 5.5 (95% CI, 5.2-5.9) months, respectively; best response, CR, and confirmed response rates were 44%, 22%, and 34%, respectively. Patient-level associations showed that PFS status at 4 months was a strong predictor of subsequent survival (hazard ratio [HR], 0.42; 95% CI, 0.35-0.51; concordance index 0.63; P < .01), with 6-month PFS being the strongest (HR, 0.41; 95% CI, 0.35-0.49; concordance index, 0.66, P < .01). At the trial level, PFS showed the highest level of surrogacy for OS (weighted least squares R(2) = 0.79; Copula R(2) = 0.80), explaining 79% of the variance in OS. Tumor response endpoints showed lower surrogacy levels (weighted least squares R(2) ≤0.48)., Conclusions: PFS was strongly associated with OS at both the patient and trial levels. PFS also shows promise as a potential surrogate for OS, but further validation is needed using data from a larger number of randomized phase 3 trials., (Copyright © 2010 American Cancer Society.)

Published
2011
Full Text
View/download PDF

23. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.

Author

Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, and Adjei AA

Subjects
Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Combined Modality Therapy, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Male, Radiotherapy adverse effects, Survival Rate, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms therapy
Abstract

Background: The objective of this study was to assess the value of combined-modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who received RT plus chemotherapy for stage III nonsmall cell lung cancer (NSCLC)., Methods: The North Central Cancer Treatment Group performed 2 recent Phase III trials for stage III NSCLC. The first trial, NCCTG 90-24-51, included 3 arms: once-daily RT (QDRT) alone, twice-daily RT (BIDRT) alone, and concurrent chemotherapy plus BIDRT. The second trial, NCCTG 94-24-52, included 2 arms and compared concurrent chemotherapy with either QDRT or BIDRT. The chemotherapy arms of both trials included etoposide and cisplatin administered concurrently with RT. Only the patients aged >/=65 years (elderly) who participated in those trials were included in this analysis., Results: Of the 166 elderly patients who were included in this analysis, 37 patients received RT alone, and 129 patients received concurrent chemotherapy plus RT. The median and 5-year survival rates were 10.5 months and 5.4% for the RT alone group compared with 13.7 months and 14.7% for the RT plus chemotherapy group (log-rank P = .05). Patients who received RT plus chemotherapy experienced significantly greater severe toxicity (grade >/=3) compared with patients who received RT alone (89.9% vs 32.4%; P < 0.01)., Conclusions: Elderly patients who participated in these trials appeared to gain a survival advantage from RT and chemotherapy compared with RT alone. As is the case with younger patients, this benefit came at the cost of additional toxicity.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results